Welcome to our dedicated page for Scilex Holding Co news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Co stock.
Scilex Holding Company (Nasdaq: SCLX) generates frequent news at the intersection of non-opioid pharmaceuticals, capital markets activity, and emerging data-tokenization initiatives. The company focuses on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain and for neurodegenerative and cardiometabolic disease, and its updates often center on this portfolio and related strategic moves.
News about Scilex commonly covers developments around its commercial products ZTlido, ELYXYB and Gloperba, as well as its late-stage candidates SP-102 (SEMDEXA), SP-103 and SP-104. Company announcements highlight clinical milestones, regulatory designations such as Fast Track status for certain candidates, and efforts to advance non-opioid therapies in indications with high unmet needs.
Investors following SCLX news will also see regular coverage of financing and corporate transactions. Recent Form 8-K filings and press releases describe warrant inducement agreements, exercises of existing warrants for cash proceeds, issuance of new warrants, non-recourse loan and securities pledge agreements backed by Scilex or Datavault AI shares, and the termination of an equity line of credit. These items provide insight into how Scilex structures its capital and manages liquidity.
Another recurring news theme is Scilex’s collaboration with Datavault AI. Announcements describe a Securities Purchase Agreement for Datavault AI stock, a pre-funded warrant, and a License Agreement for Datavault’s AI-driven data platforms in biotech and related markets. Press releases also detail Dream Bowl 2026 Meme Coin distributions by Datavault AI to eligible Scilex shareholders and Scilex’s sponsorship of the Dream Bowl 2026 event.
Visitors to this news page can review regulatory disclosures, financing updates, licensing and investment agreements, digital asset-related announcements, and other material events reported in Scilex’s press releases and SEC filings.
Scilex Holding Company (NASDAQ: SCLX) announced that the U.S. Patent and Trademark Office will issue a new patent for ELYXYB®, their acute migraine treatment drug, in late 2024. This patent strengthens Scilex's intellectual property position for ELYXYB®, a liquid, micro-encapsulation formulation of celecoxib.
ELYXYB® is the only FDA-approved, ready-to-use oral solution for acute migraine treatment in adults. It offers a non-opioid alternative to habit-forming opioids and acetaminophen. In clinical studies, ELYXYB® demonstrated pain relief in as little as 15 minutes, with significant relief compared to placebo within 45 minutes in about 50% of patients.
The U.S. oral migraine drug market was estimated at $1.8 billion in 2022, while the total acute pain market in the U.S. was approximately $3 billion in 2021. Scilex launched ELYXYB® in the U.S. in April 2023, positioning it as a fast-acting treatment with potentially lower gastrointestinal side effects compared to other NSAIDs.
Scilex Holding Company (Nasdaq: SCLX) has entered into a Master Distributor Agreement with Devart Middle East Food Supplements and CH Trading Group to expand the distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa. ZTlido® is a lidocaine topical system approved for relief of neuropathic pain associated with post-herpetic neuralgia (PHN).
Key points:
- ZTlido® is the #1 prescribed, non-opioid, branded pain medication by pain specialists in the US
- Over 1 million US patients treated since launch
- 89% patient satisfaction rate in a 2023 survey
- Designed for improved adhesion and continuous 12-hour pain relief
This agreement expands Scilex's reach in Middle East and North/South Africa markets, potentially including other products from their non-opioid pain portfolio.
Scilex Holding Company (Nasdaq: SCLX) has released preliminary unaudited financial results for July 31, 2024, showing significant growth in sales. ZTlido net sales for the month were estimated between $4.0 million to $5.0 million, representing a 48% to 85% increase compared to the same period last year. Total product net sales ranged from $4.3 million to $5.3 million, indicating a 54% to 89% growth year-over-year. These figures demonstrate Scilex's continuous sales growth, particularly in its ZTlido product line, as the company enters the third quarter of 2024. However, it's important to note that these are preliminary estimates and may be subject to change upon final review and audit.
Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has released its inaugural sustainability report. The report highlights the company's efforts in:
- Environmental stewardship: Commitment to reducing environmental footprint
- Development excellence: Improving patients' lives through innovative non-opioid pain management medicines
- Social responsibility: Ethical business practices, respecting employee rights, and fostering diversity
- Governance: Transparent corporate governance for accountability
CEO Jaisim Shah emphasized Scilex's strategy to advance patient health, foster an inclusive workforce, and reduce environmental impact. The company is committed to expanding access to non-opioid pain management products and investing in scientific excellence. This report demonstrates Scilex's commitment to innovation, responsibility, and growth in areas where they can have the greatest impact.
Scilex Holding Company (SCLX), a non-opioid pain management company, has appointed Dr. Annu Navani to its Board of Directors. Dr. Navani is a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. She is the former CEO of Comprehensive Spine and Sports Center and current CMO of Boomerang Healthcare. Dr. Navani also serves as an Adjunct Clinical Associate Professor at Stanford University School of Medicine and has extensive experience in pain management and regenerative medicine.
The appointment aims to strengthen Scilex's board with Dr. Navani's expertise in pain management and her track record in both academia and private practice. This addition is expected to support Scilex's growth and advancement of its commercial non-opioid and innovative pipeline of investigational products for acute and chronic pain therapies.
Scilex Holding Company (Nasdaq: SCLX) has entered a Memorandum of Understanding (MOU) with ACEA Therapeutics for collaboration on ZTlido®, a lidocaine topical system for neuropathic pain relief. The agreement grants ACEA exclusive rights to develop and commercialize ZTlido® in Greater China, including mainland China, Taiwan, Hong Kong, and Macau. ACEA will serve as the exclusive distributor in these territories, with a potential minimum purchase commitment once ZTlido® is locally approved.
The collaboration aims to expand Scilex's non-opioid pain management portfolio in the Greater China region. The pain management market in mainland China was valued at US$17.5 billion in 2022, with an annual growth rate of 5.64%. This partnership aligns with Scilex's mission to provide innovative non-opioid medicines to acute and chronic pain patients worldwide.
Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), and Denali Capital Acquisition Corp. (Nasdaq: DECA) have signed a letter of intent for a proposed business combination. This deal values Semnur at up to $2 billion, subject to adjustments, with an expected cash on hand of up to $40 million. The business combination aims to fund the development of SP-102 (SEMDEXA™), a non-opioid corticosteroid gel for treating sciatica. The Phase 3 trial of SP-102 met key endpoints, showing significant pain reduction and safety comparable to placebo. If approved, Semnur will become a publicly traded biopharma company, and Scilex will be the majority shareholder. The transaction is pending final agreement and shareholder approval.
Scilex Holding Company (Nasdaq: SCLX), a company specializing in non-opioid pain management products, will ring the Nasdaq Closing Bell on July 5, 2024, to celebrate the launch of GLOPERBA®, the first oral liquid medicine for the prophylactic treatment of painful gout flares. CEO Jaisim Shah and Executive Chairman Henry Ji will lead the ceremony. The company’s product portfolio includes multiple FDA-approved pain management solutions, with new pipeline programs in advanced stages. This event marks Scilex’s third non-opioid product launch in five years, highlighting its strategic focus on innovative pain management solutions.
Scilex Holding Company, under the ticker SCLX, has released its preliminary unaudited financial results for June 2024 and the second quarter of 2024. ZTlido net sales in June 2024 grew by 70% to 104% year-over-year, with quarterly growth between 28% to 42%. Total product net sales for June 2024 increased 77% to 116% year-over-year, while quarterly growth ranged from 30% to 44%. ZTlido gross sales for June reached $22 million to $26 million.
Cash reserves dropped to $7 million to $10 million from $34.1 million in the previous year. Accounts receivable increased to $38 million to $40 million from $27.6 million. Operating expenses decreased to $23 million to $26 million from $31.2 million, and net loss narrowed to $15 million to $20 million from $26.6 million last year.
This data is preliminary and unaudited, and actual results may vary significantly.
Scilex Holding Company (Nasdaq: SCLX), focused on non-opioid pain management products, announced a new distribution agreement with Endeavor Distribution Endeavor, with over 10 years of logistics experience, will distribute Scilex's products nationally.
This agreement aims to enhance the commercialization of Scilex's three non-opioid products, ZTlido, ELYXYB, and Gloperba, by leveraging Endeavor's expertise in logistics and distribution. CEO Jaisim Shah emphasized that this partnership is part of Scilex's strategy to accelerate growth and successfully launch their products to specialized point-of-care customers.
FAQ
What is the current stock price of Scilex Holding Co (SCLX)?
What is the market cap of Scilex Holding Co (SCLX)?
